"DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 "
DBV Technologies, a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical and pre-clinical data for epicutaneous immunotherapy, the basis for its Viaskin technology platform, were accepted for poster and oral presentation at the European Academy of Allergy & Clinical Immunology Congress. Viaskin Peanut is an investigational therapy which aims to deliver biologically active compounds to the immune system through the skin to potentially safeguard peanut-allergic children in the event of accidental exposure to peanuts. “By using the skin to activate the immune system, EPIT may provide potential benefit to patients with food allergies in a non-invasive manner,” said Hugh Sampson, MD, professor of pediatrics and allergy and immunology at the Icahn School of Medicine at Mount Sinai.
— Hugh Sampson, Professor, Pediatrics, Allergy and Immunology, Director Emeritus, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai
Additional coverage: Market's Insider; Nasdaq